John D. Haley
- Oncology top 1%
- HER2/EGFR in Cancer Research 13
- Cancer Cells and Metastasis 9
- Colorectal Cancer Treatments and Studies 6
- Cancer Research top 2%
- Cancer, Hypoxia, and Metabolism 8
- Molecular Biology top 2%
- PI3K/AKT/mTOR signaling in cancer 9
- RNA modifications and cancer 8
- Protein Kinase Regulation and GTPase Signaling 6
-
- Lung Cancer Treatments and Mutations 14
- Otorhinolaryngology top 5%
John D. Haley
89 papers receiving 4.7k citations
Hit Papers
Peers
Comparison fields: 5 of 126
- Oncology 1.9k
- Cancer Research 771
- Molecular Biology 2.8k
- Pulmonary and Respiratory Medicine 1.1k
- Otorhinolaryngology 126
Countries citing papers authored by John D. Haley
This map shows the geographic impact of John D. Haley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John D. Haley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John D. Haley more than expected).
Fields of papers citing papers by John D. Haley
This network shows the impact of papers produced by John D. Haley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John D. Haley. The network helps show where John D. Haley may publish in the future.
Co-authorship network
The 25 scholars most cited alongside John D. Haley, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 5 | |
| 3 | 2023 | 1 | |
| 4 | 2023 | 1 | |
| 5 | 2021 | 14 | |
| 6 | 2018 | 41 | |
| 7 | 2010 | 178 | |
| 8 | 2008 | 164 | |
| 9 | 2008 | 156 | |
| 10 | The EGFR antagonist, erlotinib, combined with a small molecule inhibitor of IGF-1R acts synergistically to inhibit proliferation and induce apoptosis in ovarian and HNSCC cells | 2007 | 3 |
| 11 | Inhibition of IGF-1R by OSI-906 potentiates efficacy of various molecular targeted agents by blocking feedback loops converging at the level of IRS-1 | 2007 | 1 |
| 12 | Differential effects for small molecule versus antibody inhibitors of EGFR: Erlotinib, but not the neutralizing antibody C225, achieves inhibition of the EGFR-HER3-Akt signaling cascade | 2007 | 1 |
| 13 | 2002 | 61 | |
| 14 | 2000 | 65 | |
| 15 | 1996 | 11 | |
| 16 | 1994 | 76 | |
| 17 | ANALYSIS OF MAMMALIAN FIBROBLAST TRANSFORMATION BY NORMAL AND MUTATED HUMAN EGF RECEPTORS | 1989 | 26 |
| 18 | 1988 | 18 | |
| 19 | 1988 | 1 | |
| 20 | 1982 | 57 |
About John D. Haley
John D. Haley is a scholar working on Oncology, Molecular Biology, Cancer Research, Occupational Therapy and Anatomy, having authored 95 papers that have together received 4.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (14 papers), HER2/EGFR in Cancer Research (13 papers), PI3K/AKT/mTOR signaling in cancer (9 papers), Cancer Cells and Metastasis (9 papers), RNA modifications and cancer (8 papers), Cancer, Hypoxia, and Metabolism (8 papers), Colorectal Cancer Treatments and Studies (6 papers) and Protein Kinase Regulation and GTPase Signaling (6 papers). The work is most often cited by research in Oncology (1.9k citations), Cancer Research (771 citations), Molecular Biology (2.8k citations), Pulmonary and Respiratory Medicine (1.1k citations) and Otorhinolaryngology (126 citations). John D. Haley has collaborated with scholars based in United States, United Kingdom and Australia. Frequent co-authors include Neil W. Gibson, Stuart Thomson, Filippo Petti, Kenneth K. Iwata, Elizabeth Buck, Graeme Griffin, Eric Brown, David Epstein, Hugh D. Niall and Alexandra Eyzaguirre. Their work appears in journals such as Molecular Cancer Therapeutics, Cancer Research, The FASEB Journal, Clinical & Experimental Metastasis and Cell Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.